美诺华(603538.SH)子公司获得非布司他片药品注册证书

Core Viewpoint - Meinuo Pharma (603538.SH) announced that its wholly-owned subsidiary, Ningbo Meinuo TianKang Pharmaceutical Co., Ltd., has received the drug registration certificate for Febuxostat tablets from the National Medical Products Administration, indicating a significant step in the treatment of hyperuricemia in gout patients [1] Group 1 - The drug is specifically indicated for the long-term treatment of hyperuricemia in patients with gout [1]